Sheheryar Kabraji

1.6k total citations · 2 hit papers
23 papers, 936 citations indexed

About

Sheheryar Kabraji is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sheheryar Kabraji has authored 23 papers receiving a total of 936 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Sheheryar Kabraji's work include Brain Metastases and Treatment (7 papers), Cancer Cells and Metastasis (5 papers) and Estrogen and related hormone effects (4 papers). Sheheryar Kabraji is often cited by papers focused on Brain Metastases and Treatment (7 papers), Cancer Cells and Metastasis (5 papers) and Estrogen and related hormone effects (4 papers). Sheheryar Kabraji collaborates with scholars based in United States, Spain and China. Sheheryar Kabraji's co-authors include Jean J. Zhao, Mari Mino–Kenudson, Sai‐Hong Ignatius Ou, Dora Dias‐Santagata, Ryohei Katayama, Marc Ladanyi, Maria E. Arcila, Mark M. Awad, Gregory J. Riely and Jeffrey A. Engelman and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Nature Cell Biology.

In The Last Decade

Sheheryar Kabraji

20 papers receiving 924 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

2013 460 citations Justin F. Gainor, Anna M. Varghese et al. Clinical Cancer Research profile →
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer

2022 163 citations Qiwei Wang, Johann S. Bergholz et al. Nature Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sheheryar Kabraji United States	11	525	525	389	216	168	23	936
Cécile Vicier France	14	229 0.4×	465 0.9×	338 0.9×	223 1.0×	122 0.7×	53	808
Smruthi Vijayaraghavan United States	10	352 0.7×	571 1.1×	412 1.1×	126 0.6×	110 0.7×	15	914
Balaji Virassamy Australia	10	246 0.5×	652 1.2×	231 0.6×	174 0.8×	360 2.1×	12	946
Karin Amundson United States	6	260 0.5×	332 0.6×	429 1.1×	156 0.7×	83 0.5×	14	781
Naoe Taira Nihira Japan	10	286 0.5×	622 1.2×	551 1.4×	131 0.6×	258 1.5×	13	1.1k
Zhi L. Teo Australia	13	214 0.4×	718 1.4×	415 1.1×	275 1.3×	470 2.8×	18	1.2k
Alexandra S. Zimmer United States	13	344 0.7×	815 1.6×	365 0.9×	110 0.5×	192 1.1×	24	1.1k
Paris Vail United States	14	239 0.5×	506 1.0×	260 0.7×	203 0.9×	100 0.6×	15	739
Shiping Jiao China	6	229 0.4×	917 1.7×	391 1.0×	127 0.6×	401 2.4×	9	1.1k
Shu-Fang Jia United States	15	299 0.6×	283 0.5×	532 1.4×	175 0.8×	127 0.8×	19	845

Countries citing papers authored by Sheheryar Kabraji

Since Specialization

Citations

This map shows the geographic impact of Sheheryar Kabraji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sheheryar Kabraji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sheheryar Kabraji more than expected).

Fields of papers citing papers by Sheheryar Kabraji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sheheryar Kabraji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sheheryar Kabraji. The network helps show where Sheheryar Kabraji may publish in the future.

Co-authorship network of co-authors of Sheheryar Kabraji

This figure shows the co-authorship network connecting the top 25 collaborators of Sheheryar Kabraji. A scholar is included among the top collaborators of Sheheryar Kabraji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sheheryar Kabraji. Sheheryar Kabraji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nardone, Agostina, Damien Friel, Francisco Hermida‐Prado, et al.. (2025). Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer. JCI Insight. 10(12). 1 indexed citations

Grinshpun, Albert, Wen Ma, Giorgio Gaglia, et al.. (2024). Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer. npj Breast Cancer. 10(1). 42–42. 3 indexed citations

Corti, Chiara, Fabio Conforti, Laura Pala, et al.. (2024). Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy. Cancer Treatment Reviews. 132. 102852–102852. 7 indexed citations

Gaglia, Giorgio, Sheheryar Kabraji, Yang Dai, et al.. (2022). Temporal and spatial topography of cell proliferation in cancer. Nature Cell Biology. 24(3). 316–326. 31 indexed citations

Ni, Jing, Sheheryar Kabraji, Shaozhen Xie, et al.. (2022). p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nature Communications. 13(1). 1473–1473. 14 indexed citations

Wang, Qiwei, Johann S. Bergholz, Liya Ding, et al.. (2022). STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nature Communications. 13(1). 163 indexed citations breakdown →

Kabraji, Sheheryar, Sarah Sammons, Amanda E.D. Van Swearingen, et al.. (2022). Abstract PD4-05: Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases (BCBM). Cancer Research. 82(4_Supplement). PD4–5. 5 indexed citations

Kabraji, Sheheryar, Liam F. Spurr, Melissa E. Hughes, et al.. (2020). Genomic profiling of breast cancer brain metastases reveals targetable alterations.. Journal of Clinical Oncology. 38(15_suppl). 2525–2525.

Kabraji, Sheheryar, Xavier Solé, Ying Huang, et al.. (2019). AKT1low quiescent cancer cells in ductal carcinoma in situ of the breast. npj Breast Cancer. 5(1). 10–10. 5 indexed citations

10.

Liu, Zongming, Yanzhi Wang, Sheheryar Kabraji, et al.. (2019). Improving orthotopic mouse models of patient-derived breast cancer brain metastases by a modified intracarotid injection method . Scientific Reports. 9(1). 622–622. 22 indexed citations

11.

Ni, Jing, Yanzhi Wang, Irmina Diala, et al.. (2019). THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES. Neuro-Oncology Advances. 1(Supplement_1). i13–i13. 1 indexed citations

12.

Wang, Yanzhi, Irmina Diala, Sheheryar Kabraji, et al.. (2019). Abstract 4832: Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases. Cancer Research. 79(13_Supplement). 4832–4832. 3 indexed citations

13.

Kabraji, Sheheryar, Jing Ni, Nancy U. Lin, et al.. (2018). Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain?. Clinical Cancer Research. 24(8). 1795–1804. 67 indexed citations

14.

Alves, Cleidson P., Ipsita Dey‐Guha, Sheheryar Kabraji, et al.. (2017). AKT1low Quiescent Cancer Cells Promote Solid Tumor Growth. Molecular Cancer Therapeutics. 17(1). 254–263. 19 indexed citations

15.

Kabraji, Sheheryar, Xavier Solé, Ying Huang, et al.. (2017). AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer. Breast Cancer Research. 19(1). 88–88. 21 indexed citations

16.

Facompre, Nicole D., Xavier Solé, Sheheryar Kabraji, et al.. (2016). JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers. Cancer Research. 76(18). 5538–5549. 37 indexed citations

17.

Gainor, Justin F., Anna M. Varghese, Sai‐Hong Ignatius Ou, et al.. (2013). A retrospective analysis of the prevalence of EGFR or KRAS mutations in patients (pts) with crizotinib-naïve and crizotinib-resistant, ALK-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 31(15_suppl). 8083–8083.

18.

Kabraji, Sheheryar, et al.. (2008). Enhance your mind. BMJ. 336(Suppl S4). 804142–804142. 1 indexed citations

19.

Korb, Erica, et al.. (2008). CPEB1 regulates β‐catenin mRNA translation and cell migration in astrocytes. Glia. 56(13). 1401–1413. 33 indexed citations

20.

Saeed, Sheikh Abdul, et al.. (2004). Mechanism of Inhibitory Action of Cyclooxygenase-2 Inhibitors in Human Platelets. Journal of Biological Sciences. 4(4). 515–520. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact